BPC February 04 update

Upcoming Biotech Stock Catalysts of 1Q 2017 - as of February 6 2017

Weekly watchlist

The last week saw a number of clinical catalysts hit the screens and as has been the case for much of 2017, the data were overwhelmingly disappointing.

Ocera Therapeutics, Inc. (NASDAQ:OCRX) started the rot on Monday when it announced that its Phase 2b trial of OCR-002 in patients with Hepatic Encephalopathy (HE) did not meet its primary endpoint. Shares were sent falling 71% to $0.60.

Tuesday saw the release of three key pieces of data from firstly Tenax Therapeutics, Inc. (NASDAQ: TENX) which announced the primary endpoints were not met in its Phase 3 LEVO-CTS trial. Shares of the company closed the week down 64% post-data. Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) collapsed to close the week down 69% post-data following news that its Phase 1/2 trial of edasalonexent (CAT-1004) for the treatment of Duchenne muscular dystrophy (DMD), did not meet the primary efficacy endpoint. Investors were also not impressed with Phase 1/2 trial data released by Dimension Therapeutics, Inc. (NASDAQ:DMTX) from its candidate, DTX101 for the treatment of adult patients with moderate/severe to severe hemophilia B. Shares closed the week down 55% post-data to $1.90.

It was not, however, all doom and gloom in the biotech space. Calithera Biosciences, Inc. (NASDAQ:CALA) announced Monday a partnership with Incyte for CB-1158 in hematology with Calithera to receive up-front $45m from Incyte. Shares of the company surged to close the week 100% higher to $9.20.

Esperion Therapeutics Inc (NASDAQ:ESPR) +29% and The Medicines Company (NASDAQ:MDCO) +21%, both surged to the upside following positive data released by Amgen (NASDAQ: AMGN) on Thursday where its PCSK9 inhibitor, Repatha met both primary and secondary endpoints in reducing the risk of cardiovascular events in its FOURIER trial. Both Esperion and The Medicines Company have late stage candidates for the treatment of Hypercholesterolemia.

Weekly Watch list as follows (some likely to be March events)

Drug Stage Catalyst

OFF episodes of Parkinson’s disease (PD)

Phase 3 Phase 3 data released February 9, 2017 - primary endpoint met.


Approved Decision on Inter Partes Review (IPR) expected March 2017. Legal event (non-clinical).

Vapendavir - SPIRITUS trial
Human rhinovirus (HRV)

Phase 2b Phase 2b top-line data released February 13, 2017 - primary endpoint not met.

KTE-C19 (ZUMA-1)
Refractory Non-Hodgkin's Lymphoma (NHL) - cancer

Phase 2 Phase 2 pivotal top-line data released September 26, 2016. Rolling BLA filing initiated December 2016 with completion expected 1Q 2017. Late breaking abstract at BMT Tandem Meeting February 26, 2017.

Telotristat etiprate
Carcinoid Syndrome

PDUFA priority review PDUFA date under priority review extended by three months to February 28, 2017.

Lower back pain

Phase 3 Data due March 2017.

Roche (RHHBY) - Perjeta + Herceptin (APHINITY)
Adjuvant HER2+ breast cancer

Phase 3 Note this trial is conducted by competitor Roche (RHHBY), NOT by Puma. The event is likely to have a significant impact on the share price of Puma (e.g. positive data would likely have a negative impact on Puma and vice versa). Data are due 1Q 2017.

Oliceridine (TRV130)
Moderate to severe acute pain

Phase 3 Phase 3 APOLLO-1 and APOLLO-2 data released February 21, 2017 - primary endpoints met.